Navigation Links
TargetScan Evaluation is Shown to Deliver Potentially Higher Cancer Detection Rate and More Accurate Assessment of Grade
Date:11/24/2008

ST. LOUIS, Nov. 24 /PRNewswire/ -- A study released recently in the British Journal of Urology detailed the results from biopsies of 140 men who received care at Washington University in St. Louis, Duke University, and the University of Michigan. The study, titled "Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer," found that TargetScan(R) template guided biopsy technology potentially produces a higher cancer detection rate and more accurate assessment of grade.

The TargetScan system combines 3-D image acquisition with a stationary probe, which helps physicians plan and execute targeted prostate biopsies through accurate needle placement within a template, which in turn, can provide confidence in identifying locations of significant cancer in the prostate.

"As physicians we are challenged to provide accurate diagnosis and define the true extent of the disease so we don't over or underestimate the significance of the cancer," said Dr. Gerald Andriole, Professor and Chief of Urology at Washington University in St Louis School of Medicine, a member of the multi-center team that conducted the evaluation of TargetScan. The study's lead author, Dr. Adam Kibel, also from Washington University, agrees. "This technology allows physicians to accurately biopsy the prostate since the location of each biopsy is calculated on the basis of the prostate's size and shape. This may allow us to more accurately find and define the disease. This may allow better monitoring of patients on active surveillance. Importantly, since the location of each biopsy site is recorded, re-biopsy or treatments can be performed with more precision."

TargetScan Touch(TM) is the most current system based on the TargetScan technology platform. TargetScan Touch was unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology annual meeting, and has been tested at several of the nation's leading medical centers.

TargetScan technology is developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University in St. Louis. "Traditional hand-manipulated devices allow the prostate gland to shift, which impedes accurate biopsy and placement accuracy. By stabilizing the prostate, physicians can now detect cancer with greater confidence," said Robert Mills, president, Envisioneering Medical Technologies.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit http://www.envisioneeringmedical.com.

KM-0022 A


'/>"/>
SOURCE Envisioneering Medical Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses
2. Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures
3. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation
4. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
5. VA Announces Expansion of Disability Evaluation System Pilot
6. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
7. Study sees need for standardized evaluation of antibody response to HIV-1
8. Hooper Holmes Announces Sale of Claims Evaluation Division
9. Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients
10. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors
11. Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... The Incentive Research Foundation is pleased ... Guide," a groundbreaking analysis of how behavioral economics can be applied to the ... IRR programs, the report highlights proven behavioral economics approaches and the powerful role ...
(Date:4/27/2017)... Austin, TX (PRWEB) , ... April 27, 2017 ... ... released its all natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve ... safe, non-toxic deodorant that actually works! , Countless deodorants flood the aisles that ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last ... American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication to ... North American professional caregivers for the prestigious award each year – identifying a ...
(Date:4/27/2017)... City (PRWEB) , ... April 27, 2017 , ... Goodcents ... will open in the Lincoln, Neb. area this year. , The first new ... summer. The second location will open at 84th and Northern Lights Drive this fall. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Are you investing in the ... water-related accidents and drownings during the summer. While most of us assume this type ... occur every day. Very few people are taking the time to learn how to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Vivify Health, the pioneer and market leader ... a very significant patent for the advancement of healthcare ... via digital health.  This landmark patent provides the company ... secures Vivify,s position as the leader in remote care.  ... first company to apply consumer mobile devices, wireless biometrics, ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: